TcLand Expression appoints two
New chairman and vp of marketing and commercial operations
The French pioneer in the development of gene expression biomarkers for unmet needs in transplantation and auto-immune disease, has also appointed Patrick Terry as chairman of the Board. Terry, a Board member since 2009, succeeds TcLand Expression ceo Alain Huriez, who had held the position since 2005.
Terry is co-founder of Genomic Health and a founder of the Personalised Medicine Coalition.
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development
Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder
The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development
Researchers identify early signs of Parkinson's in the blood
Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development
iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases
The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development